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Figure 1
were no statistically signiﬁcant group differences for any of the secondary
patient-reported outcomes at week 68.
Conclusions: A signiﬁcant weight reduction improves the knee OA patients’
symptoms, as a high proportion of patients experience an OMERACT-OARSI
response at 16 weeks. However, although the sustainability of weight loss
was signiﬁcantly better in the diet group, this trial did not provide any
evidence of a difference between continuous attention from a dietician
following a 1-year maintenance program compared to either exercise or
‘nothing’ in terms of treating OA symptoms.
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Purpose: Hyaluronic acid (HA) has been included in European League
Against Rheumatology, Osteoarthritis Research Society International, Amer-
ican College of Rheumatology, American Pain Society and American
Academy of Orthopedic Surgeons recommendations for treatment of
painful knee osteoarthritis (OA). Intra-articular (IA) sodium hyaluronate
has proven eﬃcacious and well tolerated for the treatment of pain as-
sociated with knee OA, but optimal molecular weight of HA and dosing
regimen is still not known. HYADD4-G is a novel hydrogel obtained with a
new linear (not cross- linked) derivative of HA of bacterial origin (partial
hexadecylamide of 500-730 kDa hyaluronic acid Pat. No. EU 1095064) that
shows higher viscoelastic properties than the native HA with preservation
of hyaluronan biocompatibility.
The study objective was to evaluate the eﬃcacy and tollerability of 2
different HYADD4-G dosing regimens (2 versus 3 i.a. injections) against
phosphate-buffered saline (PB-Saline) up to 6 months in patients with knee
OA.
Methods: Prospective, multicentre, parallel, randomized, double-blind
(masked observed), PB-Saline controlled, 6 months study in knee OA.
Patients: primary knee OA according to ACR criteria, Kellgren-Lawrence
II-III stage, pain on walking >40 mm on VAS at baseline. Primary outcome
measure: pain during 50 ft (15 m) walk test, measured by Visual Ana-
logue Scale (VAS) at visits 2-9. Statistical Analysis: eﬃcacy evaluated in
intent-to-treat (ITT) population. Two-sided superiority tests of 2 different
regimens of HYADD4-G vs PB-saline for all primary and secondary outcome
measures.
Results: A total of 439 patients were randomized either to HYADD4-G 2 inj.
group (n=145), HYADD4-G 3 inj. (n=150) and PB-saline (n=144). There were
no signiﬁcant differences in demographic and disease activity parameters
between groups at baseline. Symptomatic outcome measures showed a
signiﬁcant improvement from baseline in the three treatment groups. In
particular, considering the HYADD4-G 2 injections group, the mean change
(%) between baseline and ﬁnal visit for the 50 ft walk test (VAS) was -36,5
mm (-58,9%), for WOMAC pain -19,8 mm (-40,4%), for WOMAC Stiffness
-20,5 mm (-27,1%), and for WOMAC physical function -18,2 mm (-35,4%).
However, due to a huge and unexpected placebo response, for primary and
secondary endpoints, no statistically signiﬁcant differences between the
treatment groups at any of the Visits 5 to 9 were observed. In exploratory
sub-group analysis of patients with age <65 years the pain in the target
knee was improved from baseline Visit 2 to Visit 5 in all treatment groups.
The comparison regarding pain in the target knee during walk test between
the HYADD4-G 2 injections group and the PB-Saline group for patients <65
years revealed the following p-values: P=0,1561 at the ﬁrst visit after the
last injection (day 28), P=0,0267 at day 60, P=0,0397 at day 90, P=0,0499 at
day 120, and P=0,3329 at day 180 (2-sided t-test).
There were no clinically relevant and/or statistically signiﬁcant differences
between the treatment groups with regard to frequency, distribution, inten-
sity, premature termination, or seriousness, but for probable relationship
to study group and occurrence of AEs in target knee.
Conclusions: New HA formulations HYADD4-G were effective and well
tolerated in symptomatic treatment of painful knee OA. The reductions in
VAS knee pain for patients <65 years were signiﬁcantly more effective in
HYADD4-G given in a 2 IA injections than PB-saline. A clinically signiﬁ-
cant decrease in analgesic consumption, was also observed in the same
HYADD4-G study group.
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Purpose: To compare the eﬃcacy and safety of 2 proprietary based Chon-
droitin Sulphate medicinal products: Structum® 1000mg and Chondrosulf®
1200mg.
Methods: Multicentre, randomized, double-blind, double placebo, active
controlled, parallel-group study, conducted according to a non-inferiority
design. Patients aged 50-80 years with symptomatic KOA (ACR criteria)
were randomized to receive during 24 weeks either Structum 500mg BID
or Chondrosulf 400mg TID. Inclusion criteria were: global pain in the
target knee ≥ 40 mm on a 100-mm visual analog scale (VAS), Lequesne’s
Algofunctional Index (LFI) score > 7 (range: 0-24) and radiological Kellgren-
Lawrence grade 2 or 3. The primary outcome was the mean variation over
24 weeks of the global pain (VAS) and LFI score. Main secondary outcomes
were patient’s and physician’s global assessments, Omeract-OARSI respon-
ders rate, concomitant analgesics intake and quality of life (SF-12). Safety
was assessed by recording any adverse events (AE). A non-inferiority test
was performed: 95% conﬁdence interval (CI) of the difference Structum -
Chondrosulf on change of VAS and LFI scores. Predeﬁned non inferiority
limit was settled as the lower limit of the 95% CI above -5mm and -1pt
respectively for VAS and LFI scores.
Results: 837 patients were randomized: 817 analyzed in the full analysis
dataset (FAS), 692 in the per protocol (PP) analysis with no difference be-
tween groups at entry regarding demographics and disease characteristics.
The main eﬃcacy analysis (PP) showed no difference between the 2 groups
on the mean variations of pain VAS or LFI scores over 24 weeks which
varied for VAS and LFI scores by -23,9 (17,5) and -3,2 (2,4) respectively in
Structum group and by -23,8 (17,2) and -3,1 (2,4) in Chondrosulf group.
Differences for VAS and LFI were respectively 0.01 [IC95%: -2,6; 2,6] and
0,139 [IC95%: -0,2; 0,5]. The lower limit of the 2 CI were above the prede-
ﬁned non inferiority margins (-5 and -1 respectively), clearly demonstrating
the non inferiority of Structum compared to Chondrosulf. The analysis on
the FAS gave similar results. Analyses of the secondary eﬃcacy outcomes
(PP and FAS) populations showed the same trends for each treatment
with improvements of clinical relevance at W24. The overall improvement
